<?xml version="1.0" encoding="UTF-8"?>
<p id="par0355">
 <list list-type="simple" id="lis0040">
  <list-item id="lsti0090">
   <label>•</label>
   <p id="par0360">Two small-molecule compounds, VP-14637 and JNJ-2408068, block the entry of respiratory syncytial virus (RSV) into cells at low nanomolar concentrations by binding to a small hydrophobic pocket in the center of the F protein (
    <xref rid="bib0185" ref-type="bibr">Douglas et al., 2005</xref>).
   </p>
  </list-item>
  <list-item id="lsti0095">
   <label>•</label>
   <p id="par0365">The RSV F protein is also the target of the human mab palivizumab, used to prevent infection in high-risk infants (
    <xref rid="bib0250" ref-type="bibr">Georgescu and Chemaly, 2009</xref>). A new antibody, motavizumab, with a greater virus-specific binding affinity and a lower degree of nonspecific binding to host tissues, has recently been developed (
    <xref rid="bib0510" ref-type="bibr">Wu et al., 2007</xref>).
   </p>
  </list-item>
  <list-item id="lsti0100">
   <label>•</label>
   <p id="par0370">Conserved heptad repeat regions of the fusion proteins of the highly virulent paramyxoviruses, Hendra and Nipah, are the targets of peptide mimics, which block infection 
    <italic>in vitro</italic> at low nanomolar concentrations (
    <xref rid="bib0430" ref-type="bibr">Porotto et al., 2007</xref>).
   </p>
  </list-item>
  <list-item id="lsti0105">
   <label>•</label>
   <p id="par0375">The recently discovered compound RSV604 blocks the formation of RSV nucleocapsids by binding to a specific site on the N protein at submicromolar concentrations (
    <xref rid="bib0090" ref-type="bibr">Chapman et al., 2007</xref>). It is now in Phase II clinical trials.
   </p>
  </list-item>
 </list>
</p>
